ABNOM
☆ AI Dermatology — Free Service
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
relevance score : -100.0%
ReferencesKo te Q‑switched Nd:YAG laser e mohiotia ana ki te rongoa i te nevus o Ota (nevus of Ota) me ngā ahuatanga rite. I whakahaerehia e mātou he rangahau ki te kite i te pai o te mahi a te laser high‑fluence 1064 nm Q‑switched Nd:YAG ki ngā wāhi Mongolian spots i ngā wāhi rereke, kāore i te māma te kiri. I rangahaua e mātou ngā tūroro 61 me ēnei wāhi, i tirotirohia te katoa o ngā whiu e 70. Ko te haurua o ngā patunga i rongoahia ki te laser, ko ētahi i waiho kia kore e rongoa mō te whakataurite. I arotakehia e mātou ngā hua mā te whakamahi i te tauine me te taputapu e kīia nei ko te Mexameter® hei ine i ngā taumata melanin. I whaihia ngā tūroro mō te tōharite o ngā marama 14 i roto i te rōpū māimoatanga me ngā marama 18 i roto i te rōpū tirotiro. I te mutunga o te rangahau, i kitea e mātou he rerekētanga nui i roto i ngā tatauranga tauine me ngā taumata melanin i waenga i ngā rōpū rongoa me ngā rōpū kāore i tukuna, me te rōpū laser‑whakaritea e whakaatu ana i ngā hua pai ake. Ko te laser high‑fluence Q‑switched Nd:YAG, me te kore e māma te kiri, i kitea te whaihua me te haumaru mō te rongoā i ēnei wāhi rereke o Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
I ako matou i te whaihua me te haumaru o te whakamahi i tetahi maimoatanga laser motuhake mo te ABNOM, me te titiro ki nga mea ka pa ki te pai o te mahi. I titiro matou ki nga turoro 110 he ABNOM ka whiwhi i waenga i te rua me te iwa nga maimoatanga laser. I kitea e matou he pai ake te mahi o te maimoatanga i te roa o te mahi, engari kaore i te pai ki nga turoro pakeke. He pai ake te mahi mo nga turoro skin type III me nga waahi iti ake i pangia (iti iho i te 10 cm²). Ko te melasma me te ABNOM ka iti ake te whai hua o te maimoatanga. Ko te tae me te maha o nga waahi kua pa ki te ahua kaore i rereke. Tata ki te 10 % o nga turoro he waahi pouri ake i muri i te maimoatanga. He pai nga hua o te maimoatanga maha. Ko nga turoro tawhito me te skin type IV me nga waahi pouri ka kaha ake te whiwhi i nga waahi pouri i muri i te maimoatanga. Mo nga turoro me te ABNOM me te melasma, he pai ake te whakamahi i te taiaho iti‑kaha ki te karo i te kino o te melasma.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Maimoatanga
He iti rawa te awhina a ngā kai‑maama. Kāore i rite ki te melasma, ka taea te whakapai ake a ABNOM me te maimoatanga laser ka waiho kia tangohia me te kore e hoki mai anō. Ka taea te mahi maimoatanga taiaho 10 ki te 20 ngā wā hei rongoā i te ABNOM.
#QS1064 laser